Effectiveness and safety of thrombolytics for the treatment of ischemic stroke: a rapid review

Brener S
Record ID 32014001030
English
Authors' recommendations: Mortality: Based on moderate quality of evidence, there was no difference in mortality among patients who received a recombinant tissue plasminogen (rt-Pa) activator as the thrombolytic agent compared to the control group. Dependency: Based on moderate quality of evidence, there was a decrease in dependency among patients who received a thrombolytic agent compared to control group.
Details
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Stroke
  • Brain Ischemia
  • Fibrinolytic Agents
Contact
Organisation Name: Health Quality Ontario
Contact Address: Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name: EDSinfo@hqontario.ca
Contact Email: OH-HQO_hta-reg@ontariohealth.ca
Copyright: Health Quality Ontario
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.